{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"12","value":"8.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Overall survival (OS) is defined as the time from randomization to death","dispersionType":"95% Confidence Interval","groups":[{"description":"Must be refractory or intolerant to at least one line of 5FU-based chemotherapy for metastatic disease and must not have clinically symptomatic malignant small bowel obstruction. Cobimetinib (60 mgorally once daily for days 1 - 21) and atezolizumab (840 mg intravenously every 2 weeks) every 28-day cycle.","id":"OG000","title":"Small Bowel Adenocarcinoma"}],"paramType":"MEDIAN","populationDescription":"2 of the patients was not included in the analysis of PFS because their surgical cancellations were unrelated to progressive disease.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}